Haemonetics Corp. (HAE) Tops Q4 EPS by 2c, Announces Buyback Plan and Posts FY12 Guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $108.96 +1.26%
Revenue Growth %: +5.5%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +5.5%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q4 adjusted EPS of $0.85, $0.02 better than the analyst estimate of $0.83. Revenue for the quarter came in at $170 million versus the consensus estimate of $180.31 million.
Haemonetics Corp. sees FY2012 EPS of $3.50-$3.62, versus the consensus of $3.56. Haemonetics announced its fiscal 2012 annual guidance for organic revenue growth of 4-6%.
he Company announced that its Board of Directors has approved a $50 million share repurchase.
Haemonetics Corp. sees FY2012 EPS of $3.50-$3.62, versus the consensus of $3.56. Haemonetics announced its fiscal 2012 annual guidance for organic revenue growth of 4-6%.
he Company announced that its Board of Directors has approved a $50 million share repurchase.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades Haemonetics to Buy, raises price target to $123
- Silvercorp launches share buyback program for up to 4% of shares
- Haemonetics (HAE) spreader of 500 contracts of November 115 and 130 calls as share price up 2.5%
Create E-mail Alert Related Categories
Earnings, Guidance, Stock BuybacksRelated Entities
Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
